121 related articles for article (PubMed ID: 19462892)
1. [Controlled release of paclitaxel from microparticles containing PLLA and its anti-tumor activity on human ovarian carcinoma cell line].
Yang Q; Kang YQ; Wang HJ; Yin GF; Fang K; Yang K
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Mar; 40(2):212-6. PubMed ID: 19462892
[TBL] [Abstract][Full Text] [Related]
2. Characterization and biological evaluation of paclitaxel-loaded poly(L-lactic acid) microparticles prepared by supercritical CO2.
Kang Y; Wu J; Yin G; Huang Z; Liao X; Yao Y; Ouyang P; Wang H; Yang Q
Langmuir; 2008 Jul; 24(14):7432-41. PubMed ID: 18547089
[TBL] [Abstract][Full Text] [Related]
3. Tumor-targeted paclitaxel-loaded folate conjugated poly(ethylene glycol)-poly(L-lactide) microparticles produced by supercritical fluid technology.
Huang X; Zhang Y; Yin G; Pu X; Liao X; Huang Z; Chen X; Yao Y
J Mater Sci Mater Med; 2015 Feb; 26(2):95. PubMed ID: 25649516
[TBL] [Abstract][Full Text] [Related]
4. Curcuma zedoaria (Berg.) Rosc. essential oil and paclitaxel synergistically enhance the apoptosis of SKOV3 cells.
Zhou Y; Shen J; Xia L; Wang Y
Mol Med Rep; 2015 Jul; 12(1):1253-7. PubMed ID: 25777341
[TBL] [Abstract][Full Text] [Related]
5. The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors.
Lu J; Jackson JK; Gleave ME; Burt HM
Cancer Chemother Pharmacol; 2008 May; 61(6):997-1005. PubMed ID: 17701176
[TBL] [Abstract][Full Text] [Related]
6. Preparation, characterization and in vitro cytotoxicity of indomethacin-loaded PLLA/PLGA microparticles using supercritical CO2 technique.
Kang Y; Wu J; Yin G; Huang Z; Yao Y; Liao X; Chen A; Pu X; Liao L
Eur J Pharm Biopharm; 2008 Sep; 70(1):85-97. PubMed ID: 18495445
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance.
Wang L; Jia E
Drug Deliv; 2016 Jun; 23(5):1810-7. PubMed ID: 26530693
[TBL] [Abstract][Full Text] [Related]
8. Engineered multifunctional biodegradable hybrid microparticles for paclitaxel delivery in cancer therapy.
Dwivedi P; Han S; Mangrio F; Fan R; Dwivedi M; Zhu Z; Huang F; Wu Q; Khatik R; Cohn DE; Si T; Hu S; Sparreboom A; Xu RX
Mater Sci Eng C Mater Biol Appl; 2019 Sep; 102():113-123. PubMed ID: 31146981
[TBL] [Abstract][Full Text] [Related]
9. Sustained release paclitaxel-loaded core-shell-structured solid lipid microparticles for intraperitoneal chemotherapy of ovarian cancer.
Han S; Dwivedi P; Mangrio FA; Dwivedi M; Khatik R; Cohn DE; Si T; Xu RX
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):957-967. PubMed ID: 30892967
[TBL] [Abstract][Full Text] [Related]
10. Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer.
Faria RS; de Lima LI; Bonadio RS; Longo JPF; Roque MC; de Matos Neto JN; Moya SE; de Oliveira MC; Azevedo RB
Biomed Pharmacother; 2021 Oct; 142():112000. PubMed ID: 34426249
[TBL] [Abstract][Full Text] [Related]
11. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
12. Dexamethasone inhibits the effect of paclitaxel on human ovarian carcinoma xenografts in nude mice.
Hou WJ; Guan JH; Dong Q; Han YH; Zhang R
Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2902-8. PubMed ID: 24254559
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone.
Sugimura M; Sagae S; Ishioka S; Nishioka Y; Tsukada K; Kudo R
Oncology; 2004; 66(1):53-61. PubMed ID: 15031599
[TBL] [Abstract][Full Text] [Related]
14. [Induction effect of rapamycin combined paclitaxel on apoptosis of ovarian cancer cell lines A2780 and SKOV3 and the molecular mechanism].
Ma XY; Wang SX; Liu Y; Liu RH; Lu YP; Ma D
Ai Zheng; 2007 Apr; 26(4):367-70. PubMed ID: 17430653
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of 3-D tumor spheroids by timed-released hydrophilic and hydrophobic drugs from multilayered polymeric microparticles.
Lee WL; Guo WM; Ho VH; Saha A; Chong HC; Tan NS; Widjaja E; Tan EY; Loo SC
Small; 2014 Oct; 10(19):3986-96. PubMed ID: 24947558
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Effect of Graphene Oxide Coated Nanotised Apigenin with Paclitaxel (GO-NA/PTX): A ROS Dependent Mitochondrial Mediated Apoptosis in Ovarian Cancer.
Pal MK; Jaiswar SP; Dwivedi A; Goyal S; Dwivedi VN; Pathak AK; Kumar V; Sankhwar PL; Ray RS
Anticancer Agents Med Chem; 2017; 17(12):1721-1732. PubMed ID: 28443516
[TBL] [Abstract][Full Text] [Related]
17. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells.
Kim SH; Juhnn YS; Song YS
Ann N Y Acad Sci; 2007 Jan; 1095():82-9. PubMed ID: 17404021
[TBL] [Abstract][Full Text] [Related]
18. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
19. Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells.
Prinetti A; Millimaggi D; D'Ascenzo S; Clarkson M; Bettiga A; Chigorno V; Sonnino S; Pavan A; Dolo V
Biochem J; 2006 Apr; 395(2):311-8. PubMed ID: 16356169
[TBL] [Abstract][Full Text] [Related]
20. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors.
Ho EA; Soo PL; Allen C; Piquette-Miller M
J Control Release; 2007 Jan; 117(1):20-7. PubMed ID: 17113177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
